Efektivitas Penggunaan Empagliflozin terhadap Nilai HbA1c pada Pasien Diabetes Melitus Tipe 2
DOI:
https://doi.org/10.35790/msj.v5i2.45424Abstract
Abstract: Type 2 diabetes mellitus (T2DM) is the most common type of diabetes today. Lifestyle changes are one of the causes of DM problems. Patients with T2DM are usually treated with oral hypoglycemic drugs. The sodium glucose cotransporter 2 (SGLT-2) group is a type of oral hypoglycemic drug groups that plays a role in reducing HbA1c level. Empagliflozin is a drug included in the SGLT-2 group. Previous clinical trials showed that empagliflozin could lead to a reduction in HbA1c level. This study aimed to determine the effectiveness of using empagliflozin on HbA1C values in T2DM patients. This was a literature review study with data searching using three databases namely, Pubmed, Google Scholar, and Science Direct. The results obtained 10 literatures to be reviewed. All literatures showed that there was a significant effect of empagliflozin on HbA1c value of T2DM patients. In conclusion, type 2 diabetes mellitus patients using empagliflozin show significant decreases in HbA1c values.
Keywords: type 2 diabetes mellitus; empagliflozin; HbA1c; sodium glucose cotransporter 2
Abstrak: Diabetes melitus tipe 2 (DMT2) merupakan jenis diabetes yang paling umum ditemukan saat ini. Perubahan gaya hidup menjadi salah satu penyebab timbulnya masalah DM. Penyandang DMT2 biasanya diterapi dengan obat hipoglikemik oral (OHO). Golongan obat sodium glucose cotransporter 2 (SGLT-2) merupakan salah satu jenis golongan obat OHO yang berperan dalam menurunkan kadar HbA1c, salah satunya ialah empagliflozin. Penelitian sebelumnya menunjukkan peran empaglifozin dalam uji klinis dapat menyebabkan penurunan kadar HbA1c. Penelitian ini bertujuan untuk mengetahui efektivitas penggunaan empagliflozin terhadap nilai HbA1C pada pasien DMT2. Jenis penelitian ini ialah suatu literature review dengan pencarian data menggunakan tida sumber basis data yaitu, Pubmed, Google Scholar dan Science Direct. Hasil penelitian mendapatkan sebanyak 10 literatur yang dilakukan review. Kesepuluh artikel memperlihatkan adanya pengaruh bermakna dari penggunaan empagliflozin terhadap nilai HbA1c dari pasien DMT2. Simpulan penelitian ini ialah penggunaan empagliflozin pada pasien diabetes melitus tipe 2 menunjukkan terjadinya penurunan nilai HbA1c yang bermakna.
Kata kunci: diabetes melitus tipe 2; empagliflozin; HbA1c; sodium glucose cotransporter 2
References
Dudi H. A comprehensive review of diabetes mellitus: classification, symptoms, diagnosis, prevention, and treatment. Jurnal Bioteknologi dan Biosains Indonesia (JBBI). 2021;7(2):304-17. Doi:10.29122/jbbi.v7i2.4209.
Unai GG, Vicente BA, Jebari S, Asier S, Siddiqi H, Uribe KB, et al. Pathophysiology of type 2 diabetes mellitus. Int J Mol Sci. 2020;21(17):6275.
Magliano DJ, Boyko EJ, Balkau B, Barengo N. IDF Diabetes Atlas (10th ed). Brussels, Belgium: International Diabetes Federation; 2021.
Laporan Nasional Riskesdas 2018. Jakarta: Kementerian Kesehatan Republik Indonesia; 2018.
Infodatin diabetes melitus. Pusat Data dan Informasi Kementerian Kesehatan RI; 2020.
Decroli E. Diabetes Melitus Tipe 2 (1st ed). Kam A, Efendi Y P, Decroli G P, Rahmadi A, editors. Padang: Pusat Penerbitan Bagian Ilmu Penyakit Dalam Fakultas Kedokteran Universitas Andalas Padang; 2019.
Amandari E. SGLT-2 Inhibitor: pilihan terapi baru untuk penderita diabetes melitus tipe 2. Hang Tuah Medical journal. 2018;16(1):28. Doi: 10.30649/htmj.v16i1.77
Cherney DZI, Cooper ME, Tikkanen I, Pfarr E, Johansen OE, Woerle HJ, et al. Pooled analysis of phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin. Kidney Int. 2018;93(1):231-44.
Punthakee Z, Goldenberg R, Katz P. Definition, classification and diagnosis of diabetes, prediabetes and metabolic syndrome. Can J Diabetes. 2018;42(Suppl 1):S10-5. Doi: 10.1016/j.jcjd.2017.10.003
Cho YK, Lee J, Kang YM, Yoo JH, Park JY, Jung CH, et al. Clinical parameters affecting the therapeutic efficacy of empagliflozin in patients with type 2 diabetes. PLoS One. 2019;14(8):e0220667.
Kaku K, Yamamoto K, Fukushima Y, Lliev H, Yasui A. Safety and effectiveness of empagliflozin in Japanese patients with type 2 diabetes: final results of a 3-year post-marketing surveillance study. Expert Opin Drug Saf. 2022;21(10):1315-28.
Wu Q, Liu M, Fang Z, Li C, Zou F, Hu L, et al. Efficacy and safety of empagliflozin at different doses in patients with type 2 diabetes mellitus: a network meta analysis based on randomized controlled trials. J Clin Pharm Ther. 2022;47(3):270-86.
Moon JS, Kim NH, Na JO, Cho JH, Jeong IK, Lee SH, et al. Safety and effectiveness of empagliflozin in korean patients with type 2 diabetes mellitus: results from a nationwide pos marketing surveillance. Diabetes Metab J. 2023;47(2):82-91. doi: 10.4093/dmj.2021.0356.
Okada K, Hoshide S, Kato M, Kanegae H, Ishibashi S, Kario K. Safety and efficacy of empagliflozin in elderly Japanese patients with type 2 diabetes mellitus: a post hoc analysis of data from the SACRA study. J Clin Hypertens. 2021;23(4):860-9.
Aamir AH, Raja UY, Qureshi FM, Asghar A, Mahar SA, Ahmed I, et al. Safety and efficacy of empagliflozin in Pakistani Muslim patients with type 2 diabetes (SAFE-PAK); a randomized clinical trial. BMC Endocr Disord. 2022;22(1):295.
Mirabelli M, Chiefari E, Caroleo P, Vero R, Brunetti FS, Corigliano DM, et al. Long term effectiveness and safety of SGLT-2 inhibitors in an Italian cohort of patients with type 2 diabetes mellitus. J Diabetes Res. 2019;2019:3971060. Doi: 10.1155/2019/3971060
Ceriello A, Ofstad AP, Zwiener I, Kaspers S, George J, Nicolucci A. Empagliflozin reduced long-term HbA1c variability and cardiovascular death: insights from the EMPA-REG OUTCOME trial. Cardiovasc Diabetol. 2020;19(1):176.
Vaduganathan M, Inzucchi SE, Sattar N, Fitchett DH, Ofstad AP, Brueckmann M, et al. Effects of empagliflozin on insulin initiation or intensification in patients with type 2 diabetes and cardiovascular disease: Findings from the EMPA‐REG OUTCOME trial. Diabetes Obes Metab. 2021;23(12):2775-84.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Tesalonika Rawung, Jimmy Posangi, Edward Nangoy
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
COPYRIGHT
Authors who publish with this journal agree to the following terms:
Authors hold their copyright and grant this journal the privilege of first publication, with the work simultaneously licensed under a Creative Commons Attribution License that permits others to impart the work with an acknowledgment of the work's origin and initial publication by this journal.
Authors can enter into separate or additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (for example, post it to an institutional repository or publish it in a book), with an acknowledgment of its underlying publication in this journal.
Authors are permitted and encouraged to post their work online (for example, in institutional repositories or on their website) as it can lead to productive exchanges, as well as earlier and greater citation of the published work (See The Effect of Open Access).
